Get the app
US › Healthcare

Bausch + Lomb Corp (BLCO)

US · Healthcare · Medical Instruments & Supplies

$19.99+0.35%
Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue
$1.38B
Revenue YoY
+7.3%
Net profit
$32.0M
EPS
$0.34
EPS estimate
$0.21
Net margin
2.3%

EPS came in at 0.34 against a street estimate of 0.21 — a beat of 61.9%.

Key statistics

Market cap
$7.16B
Forward P/E
17.4
P/B
1.11
Book value
$18.02
EPS (TTM)
$-0.32
52-week high
$21.36
52-week low
$14.44
50-day MA
$17.46
200-day MA
$16.70
Beta
0.52

Analyst view

Analysts rate Bausch + Lomb Corp a buy (7 buy, 7 hold, 1 sell out of 15) with an average price target of $21.71.

From the latest earnings call · 2026-10-28

CONFIDENT Bausch + Lomb delivered broad-based growth, sharp margin expansion and strong cash generation, raising 2026 revenue and EBITDA guidance for the third time. Q3 FY26 U.S. Pharma grew 14%, international Pharma grew 3%; contact lens revenue increased 9% in the U.S. and 4% internationally. Analysts focused on the leadership transition, margin durability, contact-lens trends, surgical equipment weakness, pipeline opportunities and Miebo’s growth drivers. Management emphasized execution, operational efficiency, R&D prioritization and leverage reduction, while deferring some longer-term details. 2026-10-28…

Full summary in the app.

Shareholding

Insiders
87.29%
Institutions
11.26%

Largest institutional holders

FundStake
ICAHN CARL C0.98%
Oaktree Capital Management LLC0.96%
Deutsche Bank AG0.96%
D. E. Shaw & Co LP0.93%
Davidson Kempner Capital Management LP0.88%
Goldentree Asset Management LP0.74%
T. Rowe Price Associates, Inc.0.61%
Caspian Capital Partners, L.P.0.56%

Recent filings & reports

DocumentDate
Quarterly report · Q3 2026
HEADLINE NUMBERS • Reporting period: quarter and nine months ended September 30, 2026. • Shares outstanding: 357,497,374 as of October 21, 2026. •
2026-10-28
Board / officer change · Q4 2026
OTHER NOTABLE POINTS • Director Nathalie Bernier resigned from Bausch + Lomb Corporation’s Board of Directors and its Science and Technology Committe
2026-10-28
Results announced · Q4 2026
HEADLINE NUMBERS • Third-quarter 2026 revenue was $1.375 billion, up $94 million, or 7% reported and 8% on a constant currency basis, versus the thir
2026-10-28
Board / officer change · Q4 2026
HEADLINE NUMBERS • Bausch + Lomb expects to raise its full-year 2026 guidance for adjusted EBITDA excluding Acquired IPR&D, a non-GAAP measure; the f
2026-10-13
Material agreement · Q3 2026
BAUSCH + LOMB CORPORATION - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Bausch + Lomb Corporation (ticker: BLCO) is a Canadian-incorporated com
2026-08-06
Quarterly report · Q2 2026
BAUSCH + LOMB CORPORATION - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Reporting Period: Quarter ended June 30, 2026 • Company Incorporation: Canada •
2026-07-29
Results announced · Q3 2026
BAUSCH + LOMB Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $1.394 billion (up 9% reported, 8% constant currency vs. Q2 2025) • GAAP
2026-07-29
Shareholder vote results · Q2 2026
BAUSCH + LOMB CORPORATION – 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Shareholders held May 20, 2026 • Total votes cast for director election
2026-05-20

Readable in the app.

Deals & corporate news

AnnouncementDate
Full-year 2026 revenue and adjusted EBITDA guidance raised
Bausch + Lomb reported a strong third quarter and raised its full-year 2026 revenue and adjusted EBITDA guidance. Revenue increased 7% year over year to $1.375 billion, or 8% excluding curre
2026-10-28
Company expects to raise full-year 2026 adjusted EBITDA guidance
Bausch + Lomb announced that CEO Brenton Saunders is leaving and that Mr. Appio will serve as interim CEO. The company also said it expects to raise its full-year 2026 guidance for adjusted
2026-10-13
Raises full-year 2026 revenue and adjusted EBITDA guidance
Bausch + Lomb reported strong Q2 2026 results with revenue of $1.394 billion, up 9% year-over-year (8% on constant currency basis). The company raised its full-year 2026 guidance for both re
2026-07-29
Raises full-year 2026 revenue and adjusted EBITDA guidance based on strong Q1
Bausch + Lomb reported strong Q1 2026 results with revenue of $1.244 billion, up 9% year-over-year (6% excluding favorable currency effects). The company raised full-year 2026 guidance based
2026-04-29
Q4 and full-year 2025 results announced; 2026 guidance provided
Bausch + Lomb reported strong fourth-quarter and full-year 2025 results with solid revenue growth and improved profitability. The company generated $1.405 billion in Q4 revenue (10% growth r
2026-02-18

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bausch + Lomb Corp — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-11-07.